Updated safety and long term clinical outcomes in TRANSCEND NHL 001, pivotal trial of lisocabtagene maraleucel (JCAR017) in R/R aggressive NHL.
Jeremy S. Abramson(Massachusetts General Hospital), Leo I. Gordon(Northwestern University), Maria Lia Palomba(Memorial Sloan Kettering Cancer Center), Matthew A. Lunning(University of Nebraska Medical Center), Jon Arnason(Beth Israel Deaconess Medical Center), Andres Forero‐Torres(University of Alabama at Birmingham), Michael Wang(The University of Texas MD Anderson Cancer Center), David G. Maloney(Fred Hutch Cancer Center), Alison R. Sehgal(University of Pittsburgh Medical Center), Charalambos Andreadis(University of California, San Francisco), Enkhtsetseg Purev(National Institutes of Health), Scott R. Solomon, Nilanjan Ghosh(Carolinas Healthcare System), Tina Albertson, Benhuai Xie, Jacob Garcia, Tanya Siddiqi(City Of Hope National Medical Center)
Cited by 168
Abstract
7505Background: Lisocabtagene maraleucel (liso-cel; JCAR017) is a CD19-directed 4-1BB CAR T cell product administered in defined composition at a precise dose of CD8 and CD4 CAR T cells. A multicen...
Related Papers
No related papers found
Powered by citation graph analysis